HeartSciences Inc.(HSCS)Earnings, Financials & Key Ratios

HSCS•NASDAQ

$2.94

Price updated Jun 27, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryPatient monitoring and wearable diagnostics

AboutHeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.Show more

Revenue$4K-76.6%
EBITDA-$8M-32.4%
Net Income-$9M-32.7%
EPS (Diluted)-9.34+50.2%
Gross Margin-2884.71%-549.5%
EBITDA Margin-189071.61%-466.2%
Operating Margin-192013.13%-466.4%
Net Margin-201499.52%-467.4%
ROE-233.04%-33.1%

HSCS Price & Volume

HeartSciences Inc. (HSCS) stock price & volume — 10-year historical chart

Loading chart...

Pre-Commercial Liquidity Risks Cloud Clinical Development

Investment Thesis • Updated 2026Q3

VerdictNegative: The company's fundamental outlook is severely constrained by its inability to generate meaningful revenue

Growth:Contracting

Profitability:Negative

Financial Position:Vulnerable

Cash Flow:Burning

Primary Risk:Pre-commercial liquidity exhaustion

"HeartSciences Inc. remains in a precarious pre-commercial phase, characterized by negligible revenue generation and a heavy reliance on R&D spending to validate its AI-driven cardiac technology. The company's financial stability is obscured by massive stock-based compensation reaching $550.5M in 2026Q3 and significant balance sheet volatility, including a $1.7B goodwill entry. Investors should exercise extreme caution as the firm faces persistent operational cash burn and lacks a clear, self-sustaining path to commercial viability."

Verdict Logic

as evidenced by the $4,350 TTM revenue figure against substantial ongoing operational losses.

HSCS Growth Metrics

HeartSciences Inc. (HSCS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-41.63%

3 Years-32.86%

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM0.37%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM51.62%

Return on Capital

10 Years-3564.2%

5 Years-4338.01%

3 Years-5678.83%

Last Year-201.97%

Peers Comparison

Key metrics vs top competitors for HeartSciences Inc. (HSCS)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
HSCSHeartSciences Inc.Current	$2.94	$6.37M	-0.31	-76.61%	-201499.52%	-233.04%	—
IDXXIDEXX Laboratories, Inc.	$551.50	$43.8B	42.16	10.42%	24.63%	70.87%	—
IRTCiRhythm Technologies, Inc.	$118.89	$3.91B	-85.53	26.24%	-3.53%	-20.6%	—
BEATHeartBeam, Inc.	$0.68	$23.26M	-1.09	—	—	-1034.04%	—
AORTArtivion, Inc.	$23.61	$1.15B	112.43	13.59%	2.55%	2.66%	—
HOLXHologic, Inc.	$76.01	$16.97B	30.53	1.74%	13.18%	11.01%	—